High expression of IDO1 has shown a positive correlation with immune tolerance and poor prognosis in patients with melanoma, glioma, and esophageal cancer (49, 51); this finding was, to some extent, consistent with our results. This evidence concerns the gene IDO1 and central nervous system cancer.